BridgeBio and Sentynl gain EU marketing authorization for Nulibry

The European Commission (EC) has granted marketing authorization for Nulibry (fosdenopterin) for Injection as the first therapy for the treatment of patients with molybdenum cofactor deficiency (MoCD) Type A.

The drug is being developed by US biotech BridgeBio Pharma (Nasdaq: BBIO) and Sentynl Therapeutics, a USA-based subsidiary of India’s Zydus Lifesciences (BOM: 532321), whose shares rose more than 3% to 371 rupees by late afternoon trading. BridgeBio edged up 1.5% to $11.11.

MoCD Type A is an ultra-rare and progressive condition known to impact less than 150 patients globally with a median survival of four years.